Checkpoint Therapeutics rises after FDA approval of co's skin cancer drug

Checkpoint Therapeutics

16/12/2024 11:25

** Shares of drug developer Checkpoint Therapeutics  CKPT.O 
rise 8.9% to $4 in premarket trading
    ** The U.S. FDA, on Friday, approved company's drug for
treatment of a type of cancer of the outer layer of the skin
    ** The drug to be marketed under the brand name Unloxcyt is
the company's first drug that has received approval
    ** Unloxcyt is part of a class of drugs, PD-L1 antibody,
which works by binding to a protein called programmed
death-ligand 1 that helps the body's immune system in killing
cancer cells
    ** Company said it is "currently developing a commercial
launch plan" for the drug 
    ** Up to last close, stock up 60.3% YTD 

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))